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MATERIALS OF INTERNATIONAL VACTRAIN/ 
3-rd SWEDISH-UKRAINIAN CONFERENCE ON CANCER DISEASES, 
JANUARY 16–17, 2017, STOCKHOLM, SWEDEN
The scientific conference ‘‘International VACTRAIN/ 
3-rd Swedish-Ukrainian conference on cancer diseases’’ 
was held on January 16–17, 2017 at Karolinska Institutet, 
Stockholm, Sweden. These 1.5 days were filled with 
the lectures by the invited speakers and oral presenta-
tions selected on the basis of submitted abstracts from 
younger researchers. The meeting was focused on what 
we have learnt over the recent times, on the current situ-
ation, and on the important challenges for the future with 
focus on combating cancer.
The Vice-Chancellor of Karolinska Institutet Profes-
sor Karin Dahlman-Wright gave an overview on the can-
cer research at Karolinska Institutet. Cancer is an enemy 
that requires attack from all sides and with all available 
resources. Collaboration is always important to make 
big scientific breakthroughs and clearly cancer research 
is no exception. It is vital that scientific discoveries are 
translated efficiently into new treatment methods and 
programs, new medicines and techniques. Karolinska 
Institutet is at the forefront of cancer research in the 
world. More than half of the research at Karolinska Insti-
tutet is carried out together with an international party. 
As Ukraine strengthens its ties to the European Union, 
collaborations like this workshop are vital.
The head of R.E. Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology (IEPOR), the 
National Academy of Sciences of Ukraine academi-
cian Vasyl Chekhun gave a brief overview on research 
and collaborations at IEPOR. He also mentioned that 
the VACTRAIN grant allow the researchers at IEPOR, 
especially younger generation to grow profession-
ally. Dr. Kateryna Tyminska, representing Embassy 
of Ukraine in the Kingdom of Sweden stressed the 
importance of scientific collaboration in relationship 
of two countries. Plenty of the new data and ideas 
were presented by researchers from Ukraine, Sweden, 
and Poland.
Professors Klas Wiman, Sonia Lain and Galina 
Selivanova presented the data on the new cancer 
medicine, based on activation of the TP53 protein. The 
main topic of the lectures by Professors Lars Holm-
gren, Pontus Aspenström and Manuel Patarroyo was 
the involvement of laminins, cadherins and integrins 
in the structure and migration of the cancer cells. Pro-
fessor Yihai Cao told about the antiangiogenic cancer 
therapy. Professor Boris Zhivotovsky explained the 
mechanism of chemoresistance of lung adenocarci-
noma. Professor Ingemar Ernberg presented his con-
cept of cancer “attractor” cells, at the edge of tumor 
biology, mathematical modeling and system biology. 
Professors Hans-Gustaf Ljunggren and Britta Wahren 
described their work on anti-cancer immunotherapy, 
including the clinical trials. The lecture by Professor 
Svitlana Sidorenko was devoted to a putative target 
for immunotherapy, CD150.
Many interesting reports, concerning the choice 
of the targets for cancer therapy were presented by other 
Swedish and Ukrainian researchers (see selected ab-
stracts). Cancer therapy and the problems of persona-
lized cancer therapy were also in the spot of the interest. 
During conference, largely supported by the VACTRAIN 
of Horizon 2020 program, there were also the poster 
sessions, a good platform to discuss the new data criti-
cally. Over 70 researchers took part in the work of this 
conference. Definitely, this meeting helped to broaden 
the knowledge in medical science and to plan the new 
fruitful scientific works with the aim to combat cancer.
SELECTED ABSTRACTS
ENDOPLASMIC RETICULUM STRESS 
AS A KEY FACTOR OF GENOME 
REPROGRAMMING IN CANCER CELLS
O.O. Ratushna*, D.O. Minchenko, 
O.O. Riabovol, O.Y. Luzina, O.H. Minchenko
Palladin Institute of Biochemistry, NAS of Ukraine, 
Kyiv 01601, Ukraine
*E-mail: Oksana_Ratushna@hotmail.com
The endoplasmic reticulum (ER) stress represents 
the unfolded protein response to cope with the accu-
mulation of unfolded or misfolded proteins. It is required 
to maintain the functional integrity of the ER, which 
is a dynamic intracellular organelle with exquisite sensi-
tivity to alterations in homeostasis. The unfolded protein 
response is a key player in the development of differ-
ent malignant tumors. Depending on the duration and 
severity of the ER stress, it leads to cell adaptation 
or demise. This stress is a fundamental phenomenon, 
which provides a secure protection of the cells from 
different environmental challenges and is transduced 
by three major ER resident stress sensors. Activation 
of these ER stress sensors leads to transcriptional 
reprogramming of the cells. The signaling pathways 
elicited by those stress sensors have connections with 
metabolic pathways and with other plasma membrane 
receptor signaling networks. As such, the ER has an es-
sential position as a signal integrator in the cell and is in-
strumental in the different phases of tumor progression.
Inositol requiring enzyme 1 (IRE1) is the most con-
served transducer of the unfolded protein response 
and produces either adaptive (preserve ER homeo-
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stasis) or death signals through both kinase and 
endoribonuclease, including unconventional splicing 
of XBP1 mRNA and regulated IRE1-dependent decay 
of mRNA (RIDD). Splice variant of XBP1 controls 
the expression of hundreds of the unfolded protein 
response-specific genes upon global translational re-
pression to preserve ER homeostasis. We have shown 
that inhibition of IRE1 suppresses glioma cell prolife-
ration and tumor growth by affecting the expression 
of genes encoding the tumor suppressors, TNF recep-
tors and related proteins, key transcription factors and 
protein kinases, as well as numerous mitochondrial 
proteins. Moreover, inhibition of IRE1 endoribonucle-
ase activity only has stronger effect on glial cell pro-
liferation in vitro and also on glioma growth (in mouse 
orthotopic brain model) and gene expression profile. 
It concerns especially genes, encoding key regula-
tory factors, controlling cell proliferation, distinct from 
inhibition of both enzymatic activities of IRE1.
Furthermore, we have shown that hypoxia, which 
is an obligate interconnected component of malignant 
tumor growth, affects almost all studied genes. Thus, 
inhibition of IRE1 signaling network mostly modifies the 
expression of proliferation related genes, contributing 
to the rate of glioma cell proliferation. We have identi-
fied several perspective genes, whose expression was 
significantly changed in glioma cells with inhibited 
both, enzymatic activities of IRE1 and only its endori-
bonuclease. These genes, as well as IRE1 endoribo-
nuclease and kinase can be perspective targets to the 
design the novel compounds for therapeutic strategies 
to manipulate levels of ER stress in diseases. A better 
understanding of the biological role of IRE1 signaling 
network is needed to build an integrated systematic 
view on IRE1 signaling. This will be applied to develop 
novel, innovative inhibitors and activators of this sig-
naling enzyme.
THE ADAPTOR PROTEIN  
Ruk/CIN85 PARADOXICALLY ENHANCES 
EMT OF TRIPLE NEGATIVE MOUSE BREAST 
ADENOCARCINOMA 4T1 CELLS
I. Horak*, D. Shytikov, D. Geraschenko, 
L. Knopfova, L. Borsig, L. Drobot
Palladin Institute of Biochemistry, NAS of Ukraine, 
Kyiv 01601, Ukraine
*E-mail: iryna.horak@gmail.com
To coordinate cellular responses, cell surface re-
ceptors employ receptor-associated adaptor proteins 
that are composed exclusively of domains and motives 
involved in intermolecular interactions. The assembling 
of adaptor proteins-mediated supramolecular com-
plexes is regulated in dynamic and selective fashion, 
thereby influencing processing of information through 
signaling networks. Adaptor protein Ruk/CIN85 con-
sists of three SH3 domains, four blocks of proline-rich 
motives and C-terminal coiled-coil region, and acts 
as a transducer platform that participates in control 
of various physiological processes, such as apopto-
sis, ligand-induced endocytosis of receptor tyrosine 
kinases, vesicular trafficking, cell adhesion, moti-
lity, and invasion. It has been shown that high levels 
of Ruk/CIN85 contribute to the conversion of weakly 
invasive human breast adenocarcinoma MCF-7 cells 
into a more malignant phenotype. However, a number 
of issues with respect to the role of Ruk/CIN85 in breast 
carcinogenesis remain still open.
To establish syngeneic mouse model suitable for 
experiments in vivo we stably overexpressed or down-
regulated Ruk/CIN85 in triple negative mouse ad-
enocarcinoma 4T1 cells (RukUp or RukDown cells, 
respectively). As it turned out, RukUp cells acquired 
a rounded shape, whereas RukDown cells had a more 
distinct epithelial phenotype indicating that possible 
EMT/MET processes occurred in these cells. To elu-
cidate this issue, RukUp and RukDown cells were 
studied for their adhesive and invasive properties 
in vitro and also for the expression of several marker 
EMT-associated genes.
Adhesion assay of 4T1 cells showed inverse depen-
dence of adhesion to collagen type I and fibronectin 
on Ruk/CIN85 expression. We also demonstrate that 
overexpression of Ruk/CIN85 is associated with in-
creased migration and invasion through Matrigel, colla-
gen type I and fibronectin, as well as through endothelial 
cells layer. Importantly, Ruk/CIN85 down-regulation 
led to decrease in 4T1 cells motility and invasiveness 
in vitro.
Using western-blot analysis of main EMT mark-
ers (vimentin and E-cadherin) we found high levels 
of vimentin and low of E-cadherin in RukUp cells, 
and the opposite results in RukDown cells. We used 
RT2 Profiler PCR array (Qiagen) for 84 EMT-associated 
genes in order to find additional molecules involved 
in Ruk/CIN85-mediated EMT. Ruk/CIN85 was found 
to positively regulate expression of such transcription 
factors as Mitf, Zeb2, Twist, Sparc, as well as osteo-
pontin, EGFR and TGF-β. Negative effect of Ruk/
CIN85 was demonstrated for Bmp-7, Wnt, E-cadherin, 
FoxC, keratins genes Krt-7, Krt-14 and Krt-19, and 
MMP-9. These data suggest that adaptor protein 
Ruk/CIN85 is a critical regulatory component involved 
in EMT of breast cancer cells.
BIOLOGICAL CHARACTERISTICS OF TUMOR 
CELLS AT THE DIFFERENT STAGES OF EMT 
UPON EXPOSURE TO ANTICANCER DRUGS 
AND CYTOKINES
N. Bezdieniezhnykh*, O. Lykhova, R. Kocherga, 
Yu. Kudryavets
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
*E-mail: cellbank@ukr.net
Formation of a highly malignant metastatic tumor 
cell phenotype and resistance to anticancer drugs 
are associated with the implementation of epithelial-
mesenchymal transition (EMT). Thus, monitoring 
of EMT and the possible inhibition of this process could 
be helpful to inhibit the tumor progression. It is quite 
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often that anti-tumor treatment is not effective, so new 
modalities and new targets to combat cancer should 
be developed. Established cell lines, primary cultures 
of malignant cells obtained from biopsies or ascites 
of patients with epithelial cancers (breast, colorectal 
and ovarian), immunohistochemistry, and statistical 
methods were used.
We found that the majority of the primary tumor cells 
(of ascitic fluids) showed expression of mesenchymal 
markers, namely vimentin and N-cadherin. Upon cul-
turing in vitro, on the adhesively active extracellular 
matrix, expression of mesenchymal markers, for ex-
ample, the Twist and Slug transcriptional factors, was 
down-regulated. At the same time, a number of cells 
expressing the epithelial markers, namely E-cadherin, 
pan-keratin, etc. was increased. Moreover, the cells 
altered their sensitivity to anticancer drugs, despite 
the various mechanisms of drug action (ta xanes, vinca 
alkaloids, antimetabolites). Modification of the extra-
cellular matrix, i.e. growth on collagen or in spheroids, 
also significantly influenced EMT marker expression 
and sensitivity of cells to the drugs.
Next, we investigated the influence of components 
of the microenvironment, especially cytokines inter-
feron, tumor necrosis factor, and interleukins on the 
established cell lines (MCF-7, MDA-MB-231, Colo 205, 
HT-29) that show different EMT profiles. We wanted 
to find the most effective inhibitors of the EMT process, 
thus, reducing the malignancy of tumor cells. The an-
ticancer drugs, such as platinum-containing, campto-
thecins, and some others were also tested.
Concluding, we have observed a lability of phe-
notypic characteristics of the primary tumor cells, 
i.e. changes in morphology, expression of markers, 
associated with EMT, which correlated with their sen-
sitivity to anticancer drugs. We identified a number 
of biologically active agents that might shift EMT 
to either side, thus inhibiting the malignant phenotype 
of tumor cells.
ALTERNATIVE DIRECTION OF INHIBITION 
OF MALIGNANT PROPERTIES 
IN TUMOR CELLS IN VITRO AND IN VIVO 
BY GENE THERAPY WITH INF-β GENE 
IN RECOMBINANT BACULOVIRUS VECTOR
O. Lykhova1,*, L. Strokovska2, O. Kovaleva1, 
N. Bezdieniezhnykh1, N. Semesiuk1, 
I. Adamenko1, A. Vorontsova1, Yu. Kudryavets1
1R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
2Institute of Molecular Biology and Genetics, 
NAS of Ukraine, Kyiv 03680, Ukraine
*E-mail: AlexxDNA@gmail.com
The aim of the study was to investigate the influ-
ence of recombinant baculovirus containing the 
interferon-β gene (rBV/IFN) on phenotypic charac-
teristics of tumor cells in vitro: morphology, growth, 
cytogenetic characteristics and expression of proteins 
associated with proliferative activity, cell cycle regula-
tion, epithelial-mesenchymal transition (EMT), inva-
siveness, and the migration potential. Tumorigenicity 
and the metastatic potential of tumor cells after their 
transduction with rBV/IFN were studied in vivo, using 
the mouse models.
The mouse Lewis lung carcinoma cells (LL cell line) 
and melanoma cells (MM-4 cell line) were used.
Transduction of melanoma cells and lung carcinoma 
cells with rBV/IFN leads to reduction of the cell number, 
the growth rate, cell migration ability, soft agar colony 
formation, and also in inhibition of the ability to grow 
in a serum-free condition in vitro. The LL/rBV/IFN and 
MM-4/rBV/IFN cells are arrested in G0/G1 and S phases. 
Transduction of these cells with the IFN-β gene was 
accompanied with the accumulation of apoptotic cells, 
an increased level of nuclear anomalies in MM-4 cells 
and the increased frequency of mitotic pathology 
in LL cells. Moreover, transduction of LL cells with rBV/
IFN causes significant genotoxic effects: the levels 
of chromosome aberrations were increased, as well 
as the frequency of appearance of nuclear protrusions, 
polyploidy and endoreduplication.
A l s o ,  t h e  p r o d u c t i o n  o f  re c o m b i n a n t 
IFN-β by MM-4 and LL cells was accompanied 
by the changes in the expression of proteins associ-
ated with the cell cycle regulation, EMT, invasiveness 
and migration ability: expression of p19ARF and 
p21WAF1 was increased, and of N-cadherin was 
decreased in MM-4 cells. The number of E-cadherin-
positive LL cells was increased. In addition, trans-
duction of lung carcinoma cells with rBV/IFN leads 
to significant inhibition of expression of Slug and Twist. 
These changes indicate a significant inhibition of ЕМТ 
process and reversion of tumor cells to the “normal-
like” epithelial phenotype.
In result, transduction of LL carcinoma and 
MM-4 melanoma cells with rBV/IFN in vitro inhibits 
their ability to form solid tumors and lung metastases 
in the mice. Therapeutic intravenous administration 
of the rBV/IFN results in significant reduction of the 
number and volume of lung metastases in the mice.
Concluding, transduction of lung carcinoma and 
melanoma cells with rBV/IFN inhibits their sings of ma-
lignancy in vitro and in vivo, provides genotoxic effects 
in LL cells and leads to suppression of ЕМT in these 
cells.
CD150/SLAMF1 AS A NEW POTENTIAL 
TARGET FOR ANTI-TUMOR THERAPY
S.P. Sidorenko*, O. Romanets-Korbut, 
I. Gordiienko, L. Kovalevska, L. Shlapatska
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine 
*E-mail: svitasyd@yahoo.com
CD150/SLAMF1 is a prototype member of SLAM 
family within the immunoglobulin superfamily of sur-
face receptors that are widely expressed on cells within 
hematopoietic system. Six of nine SLAMF receptors 
have a paired unique immunoreceptor tyrosine-based 
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switch motif (ITSM) that serves as a docking site for 
SH2-containing proteins. In T and B lymphocytes, 
natural killer cells, macrophages and dendritic cells 
CD150 is a co-receptor molecule that mediates dif-
ferent signal transduction pathways depending on the 
availability of downstream signaling elements, espe-
cially, the adaptor protein SH2D1A/SAP. Due to highly 
glycosylated and sialylated extracellular Ig domains, 
CD150 is involved in homotypic interactions and could 
be considered as a pattern-recognizing receptor. 
It is a major entry receptor for several Morbilliviruses, 
including measles virus, and also a bacterial sensor that 
control the killing of Gram-negative bacteria. Function-
ally it serves as a bridge between innate and adaptive 
immunity.
More than 90% of lymphoid leukemia and lympho-
mas in adults have B-cell origin. Within B-cell lineage 
cell surface receptor CD150/SLAMF1 is broadly 
expressed starting from pre-B cells with up-regu-
lation toward plasma cells. However, expression 
of CD150 is rather limited on the surface of malignant 
B cells with the block of differentiation at the different 
stages of maturation. The high level of CD150 surface 
expression is observed in hairy cell leukemia, clas-
sical Hodgkin lymphoma, subtype of diffuse large 
B-cell lymphoma with activated B cell phenotype 
(ABC-DLBCL), primary cutaneous follicular centre 
B-cell lymphoma, and in 60% of chronic lymphocytic 
leukemia cases. Expression and functions of this an-
tigen outside of the hematopoietic system were not 
fully explored. We found that CD150 was expressed 
in several tumors of ectodermal origin (e.g. squamous 
cell carcinoma of uterine cervix, rectum and oral ca-
vity, basalioma), but not in their normal counterparts. 
Recently we found CD150 expression in malignant 
cells of central nervous system (CNS) tumors. Al-
though CD150 was not found in different regions 
of normal brain tissues, our immunohistochemical 
study revealed its expression in 77.6% of human CNS 
tumors, inclu ding glioblastoma, anaplastic astrocy-
toma, diffuse astrocytoma, ependymoma, and others. 
CD150 was detected in the cytoplasm, but not on the 
cell surface of glioma cell lines, and it was colocalized 
with the endoplasmic reticulum and Golgi complex 
markers. In addition to the full length mRNA of the 
conventional mCD150 splice isoform, in glioma cells 
we found a highly expressed novel CD150 transcript 
(nCD150), containing an 83 bp insert. The insert is de-
rived from a previously unrecognized exon designated 
Cyt-new, which is located 510 bp downstream of the 
transmembrane region exon, and is a specific feature 
of primate SLAMF1. Since CD150 is not revealed 
in normal brain tissues, but is expressed in 77.6% 
of CNS tumors, CD150 could be considered as a novel 
diagnostic marker for CNS tumors and a potential 
target for the therapy of gliomas, especially measles 
virus-based oncolytic therapy.
CD150/SLAMF1 ANTIGEN IN MOLECULAR 
PATHOBIOLOGY OF CHRONIC LYMPHOCYTIC 
LEUKEMIA
I. Gordiienko*, L. Shlapatska, V. Kholodniuk, 
L. Sklyarenko, S. Sidorenko
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
*E-mail: imgordiienko@gmail.com
Recent finding indicate that CD150 cell surface 
expression can be used as a surrogate prognostic 
marker of chronic lymphocytic leukemia (CLL) favo-
rable outcome. It was shown that CLL patients with high 
CD150 expression level on malignant B cells has longer 
treatment free survival and overall survival compared 
to patients, which lost CD150 cell surface expression. 
However, the mechanisms that underlie dependent 
on CD150 expression biological properties of CLL 
B cells are not fully understood. Present study was 
focused on characterization of CD150 topology and 
isoforms expression, as well as study of CD150 medi-
ated signaling pathways in CLL B cells.
For the first time, we found that in cell surface 
CD150 negative (csCD150−) CLL cases CD150 antigen 
was expressed on the protein level and was localized 
in the cytoplasm. Within cytoplasm it was colocalized 
with markers of endoplasmic reticulum, Golgi appa-
ratus and endosomes, but not lysosomes. Exclusive 
cytoplasmic CD150 expression in the part of CLL cases 
was not associated with endoplasmic reticulum stress 
or ceramide metabolism. Ligation of CD180, but not 
CD40 or BCR, leaded to slight CD150 up-regulation 
in csCD150− CLL B cells. CD150 cell surface expression 
was positively correlated with expression of cell death 
receptor CD95, BCR negative regulator — CD22 and 
receptor of Toll-like family, potential prognostic marker 
of favorable outcome — CD180. The highest level 
of CD150 colocalization on the cell surface of CLL B cells 
was observed for CD180. We found that conventional 
transmembrane mCD150 is a predominant CD150 iso-
form in CLL. However, in 20% of studied CLL cases 
nCD150 isoform was prevalent. Moreover, elevated 
mRNA expression of sCD150 isoforms was detected 
in all CLL cases, compared to normal B cells subsets. 
In csCD150+ CLL cases the basal level of tyrosine phos-
phorylation and phosphorylation of serine/threonine 
specific motifs, which are substrates for AMPK, Akt, 
PKA, PKC, CDK kinases, was higher compared to that 
in csCD150− CLL B cells. Outcome of CD150 mediated 
Akt and MAPK kinases phosphorylation in CLL B cells 
was dependent on basal phosphorylation level of these 
kinases and often demonstrated rapid p38MAPK phos-
phorylation and bimodal kinetics of Akt, ERK1/2 and 
JNK1/2 activation. Examining the transcription factors 
expression profile in CLL B cells revealed that high 
PU.1 protein expression level positively correlated 
with CD150 cell surface expression in CLL. Further-
more, CD150 signaling was involved in regulation 
of PU.1 mRNA level in csCD150+ CLL cases. We also 
found that signals via CD150, in contrary to BCR, 
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CD40 and CD180, significantly down-regulated mRNA 
expression levels of CCL3, CCL4 and IL-10 cytokines 
in CLL B cells. This may contribute to favorable clinical 
outcome of csCD150+ CLL cases.
Taken together, CLL cases are heterogeneous in cell 
surface CD150 expression as well as in CD150 iso-
forms expression.
CHANGES IN EXPRESSION OF miRNA-122, 
-200b, AND -320a AS PROGNOSTIC 
BIOMARKERS FOR BREAST CANCER
T. Borikun*, N. Lukianova, V. Chekhun
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
*E-mail: tborikun@gmail.com
High heterogeneity and diversity of breast tumors 
make the molecular characterization based on new 
biological markers very important. Recent studies have 
shown that not only genes and proteins are important 
players in tumorigenesis, but also a new class of po-
tential epigenetic tumor markers such as microRNAs 
(miRNAs). An important advantage of miRNA molecules 
is their stability in both plasma and tumor tissues.
The aim of the study was to identify the features of on-
cosuppressive miRNA-122, -200b, and -320a in breast 
cancer (BC) patients and to monitor the possible correla-
tion between their expression and cancer progression.
The study was conducted using 110 tumor samples 
and serum of the BC patients and 14 serum samples 
of healthy volunteers. The levels of miRNAs were as-
sessed using q-PCR. The expression levels of estrogen 
receptor, progesterone receptor, Her2/neu, Ki-67, 
E-cadherin, and N-cadherin were monitored by im-
munohistochemical analysis.
Each of miRNAs has a great network of targets 
involved is cellular processes, that makes them 
very promising diagnostic markers. Among variety 
of cancer-related miRNAs we choose several that 
can be used as molecular markers in BC progno-
sis and are responsible for migration, proliferation, 
epithelial-mesenchymal transition, and drug sensibil-
ity. We have found that the majority of BC tissues are 
characterized by a significant decrease in expression 
of miRNA-122 and -200b (in 93.2% and 83.1% of cas-
es, respectively). Down-regulation of miRNA-122, 
-200b, and -320a in BC tissue was associated with 
a higher staging, enhanced prolife ration, and also with 
the absence of hormone receptors (p < 0.05). Serum 
levels of miRNA-122 and -200b were associated with 
the pathological stage (p = 0.005 and p = 0.01, re-
spectively). Decrease of miRNA-320a levels in cancer 
tissue compared to normal samples was associated 
with the triple negative BC phenotype as well, and 
also with the active proliferation, hence, with cancer 
aggressiveness. Low levels of miRNA-320a in serum 
were observed in patients with lymph node metastases 
(p = 0.03).
Concluding, the established profiles of circulating 
and tumor miRNAs are associated with aggressive 
clinical course of BC. It makes the determination 
of expression of the miRNA-122, -200b, and -320a 
in the serum the base for development of noninvasive 
screening tools for BC prognosis.
THE MRPS18–2 PROTEIN AS A PUTATIVE 
MARKER OF CARCINOGENESIS
M. Mints1, M. Mushtaq2, N. Iurchenko3, 
L. Kovalevska3, L. Buchynska3, E. Kashuba2,3,*
1Department of Women’s and Children’s Health 
(KBH), Karolinska Institutet, Stockholm 17176, 
Sweden
2Department of Microbiology, Tumor and Cell 
Biology (MTC), Karolinska Institutet, Box 280, 
Stockholm 17177, Sweden
3R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, 
Kyiv 03022, Ukraine
*E-mail: Elena.Kashuba@ki.se
Endometrial cancer (EC) is one of the most 
frequent causes of cancer death among women 
in developed countries. Histopathological diagnosis 
and imaging techniques for EC are limited, thus new 
prognostic markers are needed to offer patients the 
best treatment and follow-up.
We showed that the level of mitochondrial riboso-
mal protein MRPS18–2 (S18–2) increased in EC com-
pared with the normal endometrium and hyperplasia, 
based on a study of 42 patient biopsies. Importantly, 
high expression of free E2F1 in EC correlates well with 
high S18–2 expression. The EC cell line HEC-1-A, 
which overexpresses S18–2 constitutively, showed 
an increased proliferation capacity in vitro and in vivo 
(in SCID mice). Moreover, pan-keratin, β-catenin 
and E-cadherin signals are diminished in these cells, 
compared to the parental HEC-1-A line, in contrast 
to vimentin signal that is increased. This may be as-
sociated with epithelial-mesenchymal transition.
We conclude that high expression of S18–2 and 
free E2F1, and low pan-keratin, β-catenin, and E-
cadherin signals might be a good set of prognostic 
markers for EC.
HIGH EXPRESSION LEVELS 
OF MRPS18–2 AND PRESENCE 
OF THE RB PROTEIN ARE REQUIRED 
FOR THE MAINTENANCE OF THE STEM CELL 
PHENOTYPE
M. Mushtaq1,*, L. Kovalevska2, G. Klein1, 
E. Kashuba1,2
1Department of Microbiology, Tumor and Cell 
Biology (MTC), Karolinska Institutet, Box 280,  
Stockholm 17177, Sweden
2R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
*E-mail: Muhammad.Mushtaq@ki.se
We have found that mitochondrial ribosomal protein 
MRPS18–2 (S18–2) is involved in regulation of the 
RB-dependent pathway. It binds to both hypo- and hy-
perphosphorylated RB. The binding between RB and 
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S18–2 is promoted when cytoplasmic S18–2 is tar-
geted to the nucleus, and this disrupts the association 
of E2F1 with RB, as indicated by the increased level 
of free E2F1 in the nucleus. This presumably enhances 
the RB-dependent block to S-phase entry in the cell 
cycle. We have also found overexpression of the hu-
man S18–2 in immortalized primary rat embryonic 
fibroblasts (REFs) that showed properties of embry-
onic stem cells. Elevated expression of S18–2 in stem 
cells (our fin dings and analysis of published microar-
ray data) raises the question of whether this protein 
co-operates with the RB protein in differentiation and 
carcinogenesis. We wanted to seek a relation between 
the expression of RB and S18–2 in Rb1−/− MEFs and 
stemness. We hypothesized that simultaneous expres-
sion of both proteins at the high levels might support 
stemness.
We have used transfections, inoculation into SCID 
mice, directed differentiation, quantitative polymerase 
chain reaction, immunostaining, immunohistochemis-
try, western blotting. We showed that S18–2 protein, 
together with RB, plays a crucial role in cell de-
differentiation. We have found that overexpression 
of S18–2 and RB is needed for maintenance of cell 
stemness. Such cells can differentiate into various cell 
lineages under certain conditions.
Concluding, the presence of RB and simultaneous 
expression of S18–2 at high levels are required for the 
cell stemness.
IDENTIFICATION OF NOVEL MOLECULAR 
AND GENETIC MARKERS FOR EARLY 
DETECTION AND PROGNOSIS OF EPITHELIAL 
TUMORS
O. Mankovska*, V. Kashuba
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The main topic of our research is the identifica-
tion of molecular and genetic markers for the early 
detection of epithelial tumors and prognosis of the 
course of disease. Early detection of carcinogenic 
process can lead to more successful treatment, thus, 
significantly increasing the chances for recovery. The 
investigation of non-invasive diagnostic tools, which 
can be used in clinical practice, is now the main focus 
of oncology. This problem can be solved by using 
of molecular nucleic acid markers that are present 
in biological fluids (serum, urine, semen etc).
We have developed several useful and effective 
approaches for investigation of molecular and genetic 
markers. We are studying both, genetic and epigenetic 
changes in cancers of different types, using a broad 
scale screening of their presence in clinical samples. 
The techniques and methods we use allow us to obtain 
reliable results and propose them for implementation 
in clinical practice.
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The endometrial cancer (EC) pathogenesis to a large 
extent may be determined by genotoxic effects of estro-
gen metabolites, among which the 4-hydroxyestradiol 
(4OHE2) is characterized by the most prominent DNA-
damaging properties. Genomic instability and sensitivity 
to genotoxic estrogen metabolites in cells of EC patients 
depend on the DNA repair efficiency.
The aim of the study was to analyze the level of DNA 
damage in peripheral blood lymphocytes (PBL) of EC pa-
tients after treatment with the 4OHE2 and to evaluate the 
repair efficiency of induced DNA damage.
Total 33 EC patients (mean age 60.2 ± 1.5 years) 
and 20 healthy women (mean age 55.7 ± 3.1 years) 
were included in the study. The level of DNA damage 
in PBL was measured, using comet assay and ex-
pressed by % tail DNA (% tDNA). Estradiol (E2) level 
in blood serum was assessed by ELISA (pg/ml).
Large variability in basal level of DNA damage was 
observed in PBL of EC patients (1.8–20.5% tDNA) 
as well as healthy donors (1.1–9.2% tDNA). In aver-
age, EC patients had significantly higher basal level 
of DNA damage (7.9 ± 0.9% tDNA) compared to healthy 
women (3.5 ± 0.5% tDNA) (p < 0.05). After incubation 
with 4OHE2 there was an increase in the % tDNA in PBL 
of EC patients (8.0–57.7% tDNA) as well as of healthy 
donors (7.9–46.8% tDNA). However, the average level 
of induced DNA damage in EC patients was significantly 
higher (38.9 ± 2.7% tDNA) compared to healthy women 
(25.8 ± 2.2% tDNA) (p < 0.05). To investigate the associa-
tion between the sensiti vity of PBL to 4OHE2 and estra-
diol level in the blood, we measured the concentration 
of E2 in the blood serum. We found that the blood level 
of E2 was higher (54.9 ± 4.1 pg/ml) in EC patients with 
high sensitivity of PBL to 4OHE2 than in patients with low 
sensitivity (38.2 ± 4.3 pg/ml). The higher level of unre-
paired DNA damage in PBL was observed in EC patients 
(18.6 ± 2.6% tDNA) compared to control group (13.1 ± 
1.4% tDNA). Furthermore, it was found that patients with 
high sensitivity of PBL to 4OHE2 had greater amount 
of unrepaired DNA damage (24.1 ± 4.4% tDNA) than 
women with low sensitivity (13.1 ± 1.8% tDNA).
These results indicate that PBL of EC patients 
are characterized by hypersensitivity to 4OHE2 and 
impaired DNA damage repair that is associated with 
hormonal status of women. It can be assumed that 
increased level of 4OHE2-induced genome instability 
may contribute to pathogenesis of EC.
Copyright © Experimental Oncology, 2017
